Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment reporting

Analytics

Phase 1
6(75.0%)
Phase 1/2
2(25.0%)
8Total
Phase 1(6)
Phase 1/2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07749586Phase 1/2Recruiting

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Role: lead

NCT07023731Phase 1/2Active Not Recruiting

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Role: lead

NCT06393738Phase 1Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Role: lead

SYF5394aad02994496b8f13f90cec571fd3Phase 1Recruiting

A Study to Investigate ARV-027 in Healthy Male Participants and Participants with Spinal and Bulbar Muscular Atrophy

Role: lead

SYF88402ee777854e369377d443446427efPhase 1Unknown

A Phase 1, Multi-Cohort, Open-Label, Randomized Pilot Study to Evaluate the Effect of Food and a Proton-Pump Inhibitor (esomeprazole) on the Single-Dose Pharmacokinetics of ARV-102 in Healthy Participants.

Role: lead

SYF90b8b3ffdc354f0d91a91d941f6a2b3aPhase 1Unknown

A study to compare the absorption of two tablet strengths with the absorption of a solution.

Role: lead

SYFeb53442b8787437f993237f1f2ca4770Phase 1Unknown

A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease.

Role: lead

SYFf03a1e97909d4dc596cc034b08cec0a4Phase 1Unknown

Safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-102 in healthy participants

Role: lead

All 8 trials loaded